Rti Health Solutions
Rti Health Solutions is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase II, Double-Blind, Randomised, Placebo-Controlled Trial to Evaluate the Efficacy and Tolerability of ZED1227 in Celiac Disease Subjects Experiencing Symptoms Despite Gluten-Free Diet
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants with Sjögren’s Disease.
Sponsor Otsuka Pharmaceutical Development & Commercialization Inc.
- Start (EU)
- Latest update
- Estimated end
EFC18362 - A Phase 3, multicenter, multinational, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat compared with Cerezyme in pediatric participants 2 to 11 years of age with Gaucher disease type 3 who have reached therapeutic goals with enzyme replacement therapy
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1/2, Open-Label, Multicenter Trial with a Single Ascending Dose Cohort with Unilateral Intracochlear Injection Followed by a Bilateral Injection Expansion Cohort to Evaluate the Safety, Tolerability, and Efficacy of DB-OTO in Children and Infants with Biallelic hOTOF Mutations
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A 5- year randomized, double-blind, placebo-controlled, multi-center study assessing the efficacy, safety, and tolerability of intra-articular regimens of LNA043 versus placebo in patients with symptomatic knee osteoarthritis (ONWARDS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Rti Health Solutions?
The 2026-10-09 snapshot links Rti Health Solutions to 6 distinct CTIS trials. Recorded services include A third party responsible for optional exit interviews., Complete Parent/Legal Guardian Interview, Exit Interviews, in trial interviews, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Rti Health Solutions?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Immunology, Allergy, Dermatology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Rti Health Solutions conducted?
The linked trials record locations in 21 countries, including Spain, Germany, Poland, Italy, Romania. These are trial locations, not confirmed office locations or countries where Rti Health Solutions delivered services.
What can this page tell me about Rti Health Solutions's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Rti Health Solutions. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- RTI Health Solutions
- Rti Health Solutions